The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | The EPCORE NHL-2 trial: epcoritamab plus GemOx in transplant-ineligible R/R DLBCL
Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, comments on the EPCORE NHL-2 trial (NCT04663347) of epcoritamab plus gemcitabine and oxaliplatin (GemOx) in transplant-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Dr Vitolo notes a promising response rate, making this combination a potential option for elderly patients who are ineligible for CAR-T therapy. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This study was a study focusing on diffuse large B-cell lymphoma again in the relapsed/refractory setting but for those who are not eligible for autologous stem cell transplant and are also not eligible for CAR-T treatment. This study was a combination study of standard chemotherapy second line GemOx with epcoritamab given until progression. The study enrolled 103 patients and the response rate again was over 60% and by that I mean the progression-free survival exceeding the median progression-free survival exceeding two years...
This study was a study focusing on diffuse large B-cell lymphoma again in the relapsed/refractory setting but for those who are not eligible for autologous stem cell transplant and are also not eligible for CAR-T treatment. This study was a combination study of standard chemotherapy second line GemOx with epcoritamab given until progression. The study enrolled 103 patients and the response rate again was over 60% and by that I mean the progression-free survival exceeding the median progression-free survival exceeding two years. The safety was exactly what we expected with GemOx with epcoritamab, which is that if you combine chemotherapy and bispecific antibodies, the rate of infection is a little bit higher compared to chemotherapy alone. But this would be a good option for elderly patients, indeed the median age of the study was 72 years, with relapsed/refractory DLBCL who are not eligible for CAR-T treatment, that of course remain the gold standard for the relapsed/refractory DLBCL patient.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
